Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Chemotherapy Clinical Trials

A listing of Chemotherapy medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (219) clinical trials

For more information please visit: http://clinicaltrials.gov/ct2/show/NCT01366183?term=GOG+0273&rank=1

Phase N/A

This is a multicenter, *open-label, Phase 2 study to look at how safe and effective niraparib (**a PARP inhibitor) is in women with advanced, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. Patients must have already received at least 3 chemotherapy regimens (including, but not limited to ...


You are being asked to take part in this study because you have been diagnosed with cervical cancer which is locally advanced and not suitable for surgery. The alternative to treatment on this trial is to receive standard cisplatin chemotherapy given at the same time as radiation. The purpose of ...


This research study will look at how effective niraparib (a PARP inhibitor) is compared to placebo (a pill with no medicine in it, like a sugar pill) in maintenance therapy for women who have ovarian, fallopian tube or peritoneal cancer, and have responded (complete or partial response) to front-line platinum-based ...


Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer

Treatment If you are found to be eligible to take part in this study and agree, you will have standard chemotherapy, your scheduled surgery, and then chemotherapy in combination with pembrolizumab. Neoadjuvant Treatment: You will receive standard chemotherapy treatment for three 21-day cycles, or possibly more cycles if the doctor ...


A Phase II Dose-finding Study of F-627 in Patients With Breast Cancer Receiving Myelotoxic Chemotherapy.

This phase II study was conducted at 16 clinical centers in China and planned to enroll 150 women with breast cancer who will receive chemotherapy that includes up to 4 cycles of epirubicin and cyclophosphamide, 100 mg/m2 and 600 mg/m2, respectively. Subjects would be randomized to one of three arms, ...


A Pharmacokinetics/Dynamics Ib Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

This study was a phase Ib study of the safety and pharmacokinetics/pharmacodynamics of F-627 once per cycle as prophylaxis therapy to chemotherapy in women with breast cancer. This study was conducted at two centers in China and enrolled 15 patients with breast cancer receiving TAC chemotherapy (docetaxel, doxorubicin and cyclophosphamide). ...


Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial Ovarian Fallopian Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)

This trial is a Phase 1b/2a trial designed to evaluate the safety and efficacy of adding oral AL3818 to standard platinum-based chemotherapy such as carboplatin plus paclitaxel, concurrently and continued as a maintenance therapy for up to 12 months, in subjects with recurrent or metastatic endometrial, ovarian, fallopian, primary peritoneal, ...


Women's Triple-Negative First-Line Study: A Phase II Trial of Panitumumab Carboplatin and Paclitaxel (PaCT) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy

Study Drug Administration: About 1 week before Cycle 1, if you are found to be eligible to take part in this study, you will receive a single dose of panitumumab by vein over about 1 hour. You will then receive the study drug combination for 4 cycles. Each cycle is ...


A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens

This is a Phase 2, open-label, single arm study to evaluate the safety and efficacy of niraparib in ovarian cancer patients who have received three or four previous chemotherapy regimens. Niraparib is an orally active PARP inhibitor. Niraparib will be administered once daily continuously during a 28-day cycle. Health-related quality ...